Originally presented February 27, 2019 as part of the UNC Cancer Network Medical and Surgical Oncology Lecture Series. This Self-Paced, Online Course expired April 23, 2020.

This is a Non-Credit course and does NOT offer continuing education credits.

Presenters

Stephan Moll, MD

Stephan Moll, MD
Professor of Medicine
Hemophilia and Thrombosis Center
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Anne W. Beaven, MD

Anne W. Beaven, MD
Associate Professor of Medicine
Director, Lymphoma Program
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Key 2018/2019 Developments in Lymphoma and Thrombosis/Anticoagulation

Each year, the American Society of Hematology (ASH) hosts a conference highlighting some of the latest hematologic oncology research. Join us as our speakers highlight some of the top presentations on Non-Malignant Hematology and Lymphoma from this year’s ASH conference.

Learning Outcomes

Discuss the risk/benefit of prophylactic dose apixaban or rivaroxaban in ambulatory cancer patients starting chemotherapy, who have never had a DVT or PE.
Decide which anticoagulant is best to use in the severely obese patient and the patient who has had bariatric surgery who has an indication for full dose anticoagulation.
Describe the use of brentuximab vedotin as front line treatment of patients with CD30+ Peripheral T Cell Lymphoma.
Recognize that a short course of RCHOP chemotherapy alone may be effective in treatment of young patients with low risk DLBCL.

Credits Offered

1.0 ANCC (CNE) hours of study.
1 ASRT Category A CE Credit
1.0 AMA PRA Category 1 Credit™
1.0 ACPE CE Credit
General Participation

Requirements

To receive credit for this course, you must:

Watch a lecture video recording.
Complete the lecture post test and obtain a passing score of 80% or higher.
Complete the course evaluation.
Select credit type.

Estimated course completion time: 1 hour

Disclosures

This activity has been planned and implemented under the sole supervision of the course directors, in association with the UNC Office of Continuing Professional Development (UNC CPD). Dr. Thomas Shea consults for Spectrum Pharma and receives research support from Millennium, Otsuka, GSK, BMS, Novartis and Seattle Genetics. Dr. James Coghill, MD, and CPD staff have no relevant financial relationships with commercial interests as defined by the ACCME.

The speakers, Stephan Moll, MD, and Anne Beaven, MD, have no relevant financial relationships with commercial interests as defined by the ACCME.

Accreditation

This is a Non-Credit course and does NOT offer continuing education credits.

Disclaimer

Please note: This course was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. Questions about personal health should always be referred to a physician or other health care professional.